Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen

Journal of Proteomics

Volumn 91, Issue , 2013, Pages 478-485

  Kashuba, Elena ^a,b   Eagle, Gina L ^a   Bailey, James ^a,b,c   Evans, Paul ^d   Welham, Kevin J ^a   Allsup, David ^a,c   Cawkwell, Lynn ^a,b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c CASTLE HILL HOSPITAL   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

B cell receptor; Chronic lymphocytic leukaemia; Kininogen; Proteomics

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; HIGH MOLECULAR WEIGHT KININOGEN; KININOGEN; LOW MOLECULAR WEIGHT KININOGEN; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE ACTIVATION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NORMAL HUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

B-CELL RECEPTOR; CHRONIC LYMPHOCYTIC LEUKAEMIA; KININOGEN; PROTEOMICS;

B-LYMPHOCYTES; BIOLOGICAL MARKERS; CELL SURVIVAL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; KININOGENS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHORYLATION; PROGNOSIS; PROTEOMICS; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84883643051     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.08.002     Document Type: Article

References (52)

1. Bazargan A., Tam C.S., Keating M.J. Predicting survival in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2012, 12:393-403.
2. Lin K., Sherrington P.D., Dennis M., Matrai Z., Cawley J.C., Pettitt A.R. Relationship between p53 dysfunction, CD38 expression, and IgVh mutation in chronic lymphocytic leukemia. Blood 2002, 100:1404-1409.
3. Castro J.E., Prada C.E., Loria O., Kamal A., Chen L., Burrows F.J., et al. ZAP-70 is a novel conditional Hsp90 client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in CLL. Blood 2005, 106:2506-2512.
4. Chevallier P., Penther D., Awet-Loiseau H. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002, 116:142-150.
5. Hamblin T.J., Orchard J.A., Ibbotson R.E., Davis Z., Thomas P.W., Stevenson F.K., et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002, 99:1023-1029.
6. Rassenti L.Z., Huynh L., Toy T.L., Chen L., Keating M.J., Gribben J.G., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351:893-901.
7. Hamblin T.J. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007, 20:455-468.
8. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated IgVH genes are associated with a more aggressive form of CLL. Blood 1999, 94:1848-1854.
9. Maloum K., Davi F., Merle-Beral H., Pritsch O., Magnac C., Vuillier F., et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 2000, 96:377-379.
10. Ghia P., Stamatopoulos K., Belessi C., Moreno C., Stilgenbauer S., Stevenson F., et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007, 21:1-3.
11. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of B cell chroniclymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001, 194:1625-1638.
12. Damle R.N., Ghiotto F., Valetto A., Albesiano E., Fais F., Yan X.-J., et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes: presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA. Blood 2002, 99:4087-4093.
13. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
14. Morabito F., Mangiola M., Rapezzi D., Zupo S., Oliva B., Ferraris A., et al. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. Haematologica 2003, 88:864-873.
15. Stevenson F.K., Caligaris-Cappio F. CLL: revelations from the B-cell receptor. Blood 2004, 103:4389-4395.
16. Lin T. New agents in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2010, 5:29-34.
17. Scupoli M.T., Pizzolo G. Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. Expert Rev Hematol 2012, 5:341-348.
18. Damle R.N., Batliwalla F.M., Ghiotto F., Valetto A., Albesiano E., Sison C., et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 2004, 103:375-382.
19. Grabowski P., Hultdin M., Karlsson K., Tobin G., Åleskog A., Thunberg U., et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005, 105:4807-4812.
20. Messmer B.T., Messmer D., Allen S.L., Kolitz J.E., Kudalkar P., Cesar D., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005, 115:755-764.
21. Scielzo C., Ghia P., Conti A., Bachi A., Guida G., Geuna M., et al. HS1 protein is differentially expressed in CLL patients subsets with good or poor prognosis. J Clin Invest 2005, 115:1644-1650.
22. Krysov S., Dias S., Paterson A., Mockridge C.I., Potter K.N., Smith K.-A., et al. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood 2012, 119:170-179.
23. Le Roy C., Deglesne P.-A., Chevallier N., Beitar T., Eclache V., Quettier M., et al. The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia. Blood 2012, 120:356-365.
24. Paterson A., Mockridge C.I., Adams J.E., Krysov S., Potter K.N., Duncombe A.S., et al. Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood 2012, 119:1726-1736.
25. Bernal A., Pastore R.D., Asgary Z., Keller S.A., Cesarman E., Liou H., et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001, 98:3050-3057.
26. Haas K.M., Estes D.M. Activation of bovine B cells via surface Iimmunoglobulin M cross-linking or CD40 ligation results in different B-cell phenotypes. Immunology 2000, 99:272-278.
27. Pointon J., Eagle G., Bailey J., Evans P., Allsup D., Greenman J. Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells. Oncol Rep 2010, 24:1315-1321.
28. Petlickovski A., Laurenti L., Li X.P., Marietti S., Chiusolo P., Sica S., et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005, 105:4820-4827.
29. Allsup D.J., Kamiguti A.S., Lin K., Sherrington P.D., Matrai Z., Slupsky J.R., et al. B-cellreceptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of CLL. Cancer Res 2005, 65:7328-7337.
30. Potter K.N., Mockridge C.I., Neville L., Wheatley I., Schenk M., Orchard J., et al. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clin Cancer Res 2006, 12:1672-1679.
31. Silver K., Cornall R.J. Isotype control of B cell signaling. Sci STKE 2003, 2003:21.
32. Smith L., Welham K.J., Watson M.B., Drew P.J., Lind M.J., Cawkwell L. The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol Res 2007, 16:497-506.
33. Valceckiene V., Kontenyte R., Jakubauskas A., Griskevicius L. Selection of reference genes for quantitative polymerase chain reaction studies in purified B cells from B cell chronic lymphocytic leukaemia patients. Br J Haematol 2010, 151:232-238.
34. Kitamura N., Kitagawa H., Fukushima D., Takagaki Y., Miyata T., Nakanishi S. Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 1985, 260:8610-8617.
35. Schmaier A.H. The plasma kallikrein-kinin system counterblanaces the renin-angiotensin system. J Clin Invest 2002, 109:1007-1009.
36. Sainz I.M., Pixley R.A., Colman R.W. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 2007, 98:77-83.
37. Liu Y., Pixley R., Fusaro M., Godoy G., Kim E., Bromberg M.E., et al. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Oncogene 2009, 28:2756-2765.
38. Kolte D., Osman N., Yang J., Shariat-Madar Z. High molecular weight kininogen activates B2 receptor signaling pathway in human vascular endothelial cells. J Biol Chem 2011, 286:24561-24571.
39. Renné T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012, 34:31-41.
40. Colman R.W., White J.V., Scovell S., Stadnicki A., Sartor R.B. Kininogens are antithrombotic proteins in vivo. Arterioscler Thromb Vasc Biol 1999, 19:2245-2250.
41. Hassan S., Sainz I.M., Khan M.M., Bradford H.N., Isordia-Salas I., Kashem S.W., et al. Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo. Am J Physiol Heart Circ Physiol 2007, 292:H2959-H2965.
42. Wu J., Akaike T., Hayashida K., Miyamoto Y., Nakagawa T., Miyakawa K., et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002, 98:29-35.
43. Seegers H.C., Avery P.S., McWilliams D.F., Haywood L., Walsh D.A. Combined effect of bradykinin B2 and neurokinin-1 receptor activation on endothelial cell proliferation in acute synovitis. Faseb J 2004, 18:762-764.
44. Schulze-Topphoff U., Prat A., Bader M., Zipp F., Aktas O. Roles of the kallikrein/kinin system in the adaptive immune system. Int Immunopharmacol 2008, 8:155-160.
45. Colman R.W., Sartor R.B., Adam A.A., DeLa Cadena R.A., Stadnicki A. The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis. Clin Rev Allergy Immunol 1998, 16:365-384.
46. Barbasz A., Guevara-Lora I., Rapala-Kozik M., Kozik A. Kininogen binding to the surfaces of macrophages. Int Immunopharmacol 2008, 8:211-216.
47. Stevenson F.K., Krysov S., Davies A.J., Steele A.J., Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118:4313-4320.
48. MD-v Minden, Ubelhart R., Schneider D., Wossning T., Bach M.P., Buchner M., et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012, 489:309-312.
49. Mathis S.A., Criscimagna N.L., Leeb-Lundberg L.M. B1 and B2 kinin receptors mediate distinct patterns of intracellular Ca2+ signaling in single cultured vascular smooth muscle cells. Mol Pharmacol 1996, 50:128-139.
50. Wang Q., Patton W.F., Hechtman H.B., Shepro D. Activation of endothelial cell kinin receptors leads to intracellular calcium increases and filamin translocation: regulation by protein kinase C. Cell Signal 1997, 9:595-602.
51. Werry T.D., Wilkinson G.F., Willars G.B. Mechanisms of cross-talk between G-protein-coupled receptors resulting in enhanced release of intracellular Ca2+. Biochem J 2003, 374:281-296.
52. Montana V., Sontheimer H. Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci 2011, 31:4858-4867.